NPPA: Ceiling price of scheduled formulations revised

The NPPA has revised/ increased the ceiling price of 883 scheduled formulations in compliance of the provisions of Drugs (Price Control) Order 2013.

The Authority conducted a meeting on 31.03.2020 noted with satisfaction that the supply disruption of APIs caused by COVID-19 outbreak is returning to normalcy and no unusual price fluctuations in price of inputs for medicines, amid COVID-19 outbreak has been reported. Thus, normal price revisions have been allowed.

The Wholesale Price Index increase has been based on the data published by Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry, Government of India. Increase in ceiling price is based on Wholesale Price Index (WPI) is 1.88468 percent.

The revision in ceiling price of formulations also includes the revision of ceiling price of cardiac stents also.

The revised prices will be applicable from 1st April 2020 and the detail of revised prices is available on NPPA’s website

  • Related Posts

    Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

    Dr Rajendra Pratap Gupta gets nominated to advise UN Secretary General Geneva/ New Delhi: Former advisor to Union Health Minister of India JP Nadda in his earlier stint and a…

    IPC releases draft NFI-2026 to promote rational use of medicines

    Ghaziabad:- The Indian Pharmacopoeia Commission (IPC) has taken a significant step toward strengthening public health systems with the draft release of the National Formulary of India (NFI) 2026, a comprehensive…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’